GGrantIndex
Sort

261,768 grants matching gene therapy

Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Moderate to Severe Flares: A Phase 3 Multi-Center, Randomized, Double-Blind, Sham-Controlled Trial

$2,439,584
Parambir Singh Dulai · Northwestern University At Chicago · U01 · FY2023 · DK

Comparative Genomics of Longevity

$2,439,250
Vera Gorbunova · University Of Rochester · P01 · FY2019 · AG

WEILL CORNELL PROGRAM OF EXCELLENCE IN GENE THERAPY

$2,439,199
Weill Medical College Of Cornell Univ · U01 · FY2002 · HL

Mayo Clinic Breast Cancer SPORE

$2,438,534
Matthew Philip Goetz · Mayo Clinic Rochester · P50 · FY2017 · CA

University of Texas MD Anderson SPORE in Ovarian Cancer

$2,438,308
University Of Texas Md Anderson Can Ctr · P50 · FY2005 · CA

SPORE: Targeted Therapies for Glioma

$2,438,174
Tracy T Batchelor · Brigham And Women'S Hospital · P50 · FY2019 · CA

Cell-Type Specific Vulnerability to Tauopathy and Its Prevention in Multiple Models

$2,438,130
Einar M Sigurdsson · New York University School Of Medicine · RF1 · FY2021 · NS

Mitochondrial and Metabolic Dysfunction in Age-related Neurodegeneration

$2,437,958
Gary E Gibson · Winifred Masterson Burke Med Res Inst · P01 · FY2016 · AG

Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)

$2,437,131
Joel Moss · National Heart, Lung, And Blood Institute · ZIA · FY2009 · HL

Exploration of the TranslationalTherapeutic Potential of Stem Cell B

$2,437,089
Howard Fine · Basic Sciences · Z01 · FY2007 · CA

Brooklyn Women's Interagency HIV Study (WIHS) V

$2,436,591
Howard Minkoff · Suny Downstate Medical Center · U01 · FY2017 · AI

Lentiviral Gene Therapy for Sickle Cell Disease and Immunodeficiency Disorders

$2,436,444
Brian P Sorrentino · St. Jude Children'S Research Hospital · P01 · FY2011 · HL

Targeting the Epigenetic and Metabolic Control of EBV-Epithelial Cancers

$2,436,054
Paul M. Lieberman · Wistar Institute · P01 · FY2023 · CA

SPORE in Prostate Cancer

$2,436,043
Howard I Scher · Sloan-Kettering Inst Can Research · P50 · FY2017 · CA

Development and Validation of Therapy for Mucopolysaccharidosis III

$2,435,870
Jill Wood · Phoenix Nest, Inc. · U44 · FY2022 · NS

Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors (SOARS-B)

$2,435,695
Linmarie Sikich · Univ Of North Carolina Chapel Hill · U01 · FY2013 · HD

Novel Molecular Mechanisms Promote GPCR-Induced Bronchodilation in Asthma

$2,435,478
Reynold Alexander Panettieri · Rutgers Biomedical/Health Sciences-Rbhs · P01 · FY2017 · HL

Integrating innate and adaptive pathways in vaccine responses

$2,435,437
Jeffrey Victor Ravetch · Rockefeller University · U19 · FY2014 · AI

Adenovirus-vectored nasal anthrax vaccine

$2,435,173
Vaxin Inc. · UC1 · FY2005 · AI

Biological Variation in Hemophilia

$2,434,893
John S. Lollar · Emory University · U54 · FY2014 · HL

Biological Variation in Hemophilia

$2,434,741
John S. Lollar · Emory University · U54 · FY2016 · HL

The Memorial Sloan Kettering Cancer Center SPORE in Pancreas Cancer

$2,434,565
Eileen Mary O'Reilly · Sloan-Kettering Inst Can Research · P50 · FY2025 · CA

Single Cell Transcriptomic and Epigenomic Dissection of Opioid and Cocaine Responses in HIV

$2,433,874
Manolis Kellis · Broad Institute, Inc. · U01 · FY2023 · DA

"Genetic and clinical studies of Gaucher disease and other lysosomal disorders"

$2,433,208
Ellen Sidransky · National Human Genome Research Institute · ZIA · FY2015 · HG

Role of Macrophages in Impaired Wound Healing in Type 1 Diabetes

$2,432,818
Aristidis Veves · Beth Israel Deaconess Medical Center · DP3 · FY2015 · DK